Baxalta (now part of Shire)
Clinical trials sponsored by Baxalta (now part of Shire), explained in plain language.
Baxalta was a biopharmaceutical company acquired by Shire, which is now part of Takeda.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Single gene shot could tame hemophilia b bleeding
Disease control OngoingThis study tests a single intravenous dose of a gene therapy called AskBio009 in up to 30 adults with severe hemophilia B. The therapy delivers a working copy of the factor IX gene to help the body produce its own clotting factor. The main goal is to check safety, but researchers…
Phase 1/2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Hemophilia drug safety under the microscope: real-world study launched
Knowledge-focused OngoingThis study follows 207 people with hemophilia A who are already taking ADYNOVI/ADYNOVATE to prevent bleeding. Researchers want to see if any long-term side effects appear during normal use. The goal is to gather safety information, not to test if the drug works.
Sponsor: Baxalta now part of Shire • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC